Akari Therapeutics Statistics Share Statistics Akari Therapeutics has 16.09K
shares outstanding. The number of shares has increased by 164.95%
in one year.
Shares Outstanding 16.09K Shares Change (YoY) 164.95% Shares Change (QoQ) -99.87% Owned by Institutions (%) 0.56% Shares Floating 16.02K Failed to Deliver (FTD) Shares 558 FTD / Avg. Volume 2.3%
Short Selling Information The latest short interest is 36.7K, so 0.11% of the outstanding
shares have been sold short.
Short Interest 36.7K Short % of Shares Out 0.11% Short % of Float 0.18% Short Ratio (days to cover) 2.45
Valuation Ratios PE Ratio 0 Forward PE -2.16 PS Ratio 0 Forward PS 0 PB Ratio 0 P/FCF Ratio 0 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Akari Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.15,
with a Debt / Equity ratio of 0.15.
Current Ratio 0.15 Quick Ratio 0.15 Debt / Equity 0.15 Debt / EBITDA -0.15 Debt / FCF -0.26 Interest Coverage 88.7
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-2.47M Employee Count 8 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -68.75% in the
last 52 weeks. The beta is 0.23, so Akari Therapeutics's
price volatility has been higher than the market average.
Beta 0.23 52-Week Price Change -68.75% 50-Day Moving Average 1.15 200-Day Moving Average 1.3 Relative Strength Index (RSI) 35.59 Average Volume (20 Days) 24,283
Income Statement
Revenue n/a Gross Profit n/a Operating Income -21.64M Net Income -19.79M EBITDA -21.64M EBIT -20.04M Earnings Per Share (EPS) -160
Full Income Statement Balance Sheet The company has 2.6M in cash and 3.26M in
debt, giving a net cash position of -661K.
Cash & Cash Equivalents 2.6M Total Debt 3.26M Net Cash -661K Retained Earnings -247.25M Total Assets 50.96M Working Capital -17.56M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -12.55M
and capital expenditures 0, giving a free cash flow of -12.55M.
Operating Cash Flow -12.55M Capital Expenditures n/a Free Cash Flow -12.55M FCF Per Share -1050.9
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields AKTX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for AKTX is $5,
which is 376.2% higher than the current price. The consensus rating is "Buy".
Price Target $5 Price Target Difference 376.2% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Aug 21, 2023. It was a
backward
split with a ratio of 1:20.
Last Split Date Aug 21, 2023 Split Type backward Split Ratio 1:20
Scores Altman Z-Score -8.45 Piotroski F-Score 2
